Page 66 - 2018_12-Haematologica-web

V. Madan et al.
Somatic mutational landscape of AML
with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia. 2016;30(2):501-504.
7. Krauth MT, Eder C, Alpermann T, et al. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome. Leukemia. 2014;28(7):1449-1458.
8. Duployez N, Marceau-Renaut A, Boissel N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127(20):2451-2459.
9. Faber ZJ, Chen X, Gedman AL, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016; 48(12):1551-1556.
10. Yamato G, Shiba N, Yoshida K, et al. ASXL2 Mutations are Frequently Found in Pediatric AML Patients with t(8;21)/RUNX1-RUNX1T1 and Associated with a Better Prognosis. Genes Chromosomes Cancer. 2017;56(5):382-393.
11. Hatlen MA, Arora K, Vacic V, et al. Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. J Exp Med. 2016;213(1):25-34.
12. Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer. 2013;109(2):299-306.
13. Katoh M. Functional proteomics of the epi- genetic regulators ASXL1, ASXL2 and ASXL3: a convergence of proteomics and epigenetics for translational medicine. Expert Rev Proteomics. 2015;12(3):317-328.
14. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241-247.
15. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloprolifer- ative neoplasms. Leukemia. 2009; 23(11):2183-2186.
16. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2012;44(1):47-52.
17. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
18. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med. 2015;373(1):35-47.
19. Abdel-Wahab O, Pardanani A, Patel J, et al. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia. 2011;25(7):1200-1202.
20. Boultwood J, Perry J, Zaman R, et al. High- density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia dur- ing disease progression. Leukemia. 2010;24(6):1139-1145.
Efficient analysis, visualization and sum- marization of MAF files from large-scale cohort based cancer studies. bioRxiv. 2016 May 11. Available from: http://doi.org/ 10.1101/052662
35. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-
21. Abdel-Wahab O, Gao J, Adli M, et al.
Deletion of Asxl1 results in myelodysplasia
and severe developmental defects in vivo. J
Exp Med. 2013;210(12):2641-2659. 510.
22. Farber CR, Bennett BJ, Orozco L, et al. Mouse genome-wide association and sys- tems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastoge- nesis. PLoS Genet. 2011;7(4):e1002038.
23. Lai HL, Grachoff M, McGinley AL, et al. Maintenance of adult cardiac function requires the chromatin factor Asxl2. J Mol Cell Cardiol. 2012;53(5):734-741.
24. Baskind HA, Na L, Ma Q, Patel MP, Geenen DL, Wang QT. Functional conservation of Asxl2, a murine homolog for the Drosophila enhancer of trithorax and poly- comb group gene Asx. PLoS One. 2009;4(3):e4750.
25. McGinley AL, Li Y, Deliu Z, Wang QT. Additional sex combs-like family genes are required for normal cardiovascular devel- opment. Genesis. 2014;52(7):671-686.
26. Lai HL, Wang QT. Additional sex combs- like 2 is required for polycomb repressive complex 2 binding at select targets. PLoS One. 2013;8(9):e73983.
27. Micol JB, Pastore A, Inoue D, et al. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun. 2017;8(15429.
28. Li J, He F, Zhang P, et al. Loss of Asxl2 leads to myeloid malignancies in mice. Nat Commun. 2017;8:15456.
29. Madan V, Shyamsunder P, Han L, et al. Comprehensive mutational analysis of pri- mary and relapse acute promyelocytic leukemia. Leukemia. 2016;30(12):2430.
30. Faust GG, Hall IM. SAMBLASTER: fast duplicate marking and structural variant read extraction. Bioinformatics. 2014; 30(17):2503-2505.
31. Koboldt DC, Zhang Q, Larson DE, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22(3):568-576.
32. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17(1):122.
33. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point muta- tions in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213- 219.
34. Mayakonda A, Koeffler HP. Maftools:
36. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and character- ization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med. 1991;173(5):1213-1225.
37. Tonks A, Pearn L, Musson M, et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human pro- genitor cells and in acute myeloid leukaemia. Leukemia. 2007;21(12):2495- 2505.
38. Chyla BJ, Moreno-Miralles I, Steapleton MA, et al. Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Mol Cell Biol. 2008;28(20):6234-6247.
39. Athanasiadou A, Stalika E, Sidi V, Papaioannou M, Gaitatzi M, Anagnostopoulos A. RUNX1-MTG16 fusion gene in de novo acute myeloblastic leukemia with t(16;21)(q24;q22). Leuk Lymphoma. 2011;52(1):145-147.
40. Lavallee VP, Lemieux S, Boucher G, et al. RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. Blood. 2016;127(20):2498- 2501.
41. Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. J Hematol Oncol. 2012;5:12.
42. Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013;27(1):82-91.
43. Hartmann L, Dutta S, Opatz S, et al. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation. Nat Commun. 2016;7:11733.
44. Douglas D, Hsu JH, Hung L, et al. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 2008;68(16):6507-6515.
45. Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol. 2007; 27(10):3769-3779.
1990
haematologica | 2018; 103(12)